<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11465">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957682</url>
  </required_header>
  <id_info>
    <org_study_id>R727-CL-1532</org_study_id>
    <secondary_id>2016-003189-16</secondary_id>
    <nct_id>NCT02957682</nct_id>
  </id_info>
  <brief_title>Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect on mental state (known as
      &quot;neurocognitive function&quot;) with use of Praluent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Cambridge Neuropsychological Test Automated Battery cognitive domain Spatial Working Memory strategy score</measure>
    <time_frame>Baseline to week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory neurocognitive Paired Associates Learning (PAL); defined as both a PAL z-score change from baseline and PAL raw score change from baseline</measure>
    <time_frame>Baseline to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory neurocognitive Reaction Time (RTI); RTI z-score change from baseline and RTI raw score change from baseline</measure>
    <time_frame>Baseline to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory neurocognitive Spatial Working Memory (SWM) between-errors score; defined as both a SWM between-errors z-score change from baseline and SWM between-errors raw score change from baseline</measure>
    <time_frame>Baseline to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Composite score from baseline; defined as (the average of the following 4 measures at week 96: SWM strategy z-score, PAL z-score, RTI z-score, and the SWM between-errors z-score) minus the average of the same 4 z-score measures at baseline</measure>
    <time_frame>Baseline to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in calculated low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in apolipoprotein (Apo) B</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change non-high-density lipoprotein cholesterol (HDL-C),</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in total cholesterol (Total-C)</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in lipoprotein a [Lp(a)]</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in HDL-C</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in triglyceride (TG)</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in apolipoprotein A-1</measure>
    <time_frame>Change from baseline to weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients reaching LDL-C &lt;70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>At weeks 12, 24, 48, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients reaching LDL-C &lt;50 mg/dL (1.29 mmol/L)</measure>
    <time_frame>At weeks 12, 24, 48, 72, and 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2170</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Praluent Regimen - Administration through subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo matching Praluent - Administration through subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praluent (Alirocumab)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ age 40 years and ≤ age 85 years

          -  Patients with heterozygous familial hypercholesterolemia (heFH) or with non-familial
             hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk

          -  Patients with history of coronary heart disease (CHD) not having adequate control of
             their hypercholesterolemia with LDL-C ≥70 mg/dL, or all other patients with LDL-C
             ≥100 mg/dL and be on maximally-tolerated dose of statin (unless they are
             statin-intolerant)

          -  Patients must have successfully completed the Motor Screening Task

          -  Patients must be willing and able to comply with clinic visits and study related
             procedures

          -  Patients must provide signed informed consent

        Exclusion Criteria:

          -  Patients with known Alzheimer's disease or other dementia, schizophrenia, bipolar
             disorder, severe depression, cognitive impairment, or patients with a sleep disorder
             requiring daily pharmacological treatment

          -  Recent (within 3 months prior to the screening visit) myocardial infarction, unstable
             angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous
             coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting,
             stroke, transient ischemic attack, carotid revascularization, endovascular procedure
             or surgical intervention for peripheral vascular disease

          -  Certain laboratory findings obtained during the screening visit

          -  Any condition or situation, including other significant mental or neurological
             disorders that, in the investigator's opinion, may confound the study results, or may
             interfere significantly with the patient's participation in the study

          -  Pregnant or breastfeeding women

          -  A positive human immunodeficiency virus (HIV) test

        The information listed above is not intended to contain all considerations relevant to a
        patient's potential participation in this clinical trial and not all inclusion/exclusion
        criteria are listed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Manizales</city>
        <state>Caldas</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <state>D.c.</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <state>Valle del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>October 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
